Janice Liu, MD
Gynecologic Oncology · Ypsilanti, MINPI 1699868752
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $100 of the $116 with a category attached, or 85.9%. Coopersurgical, Inc. accounts for 85.9% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for gynecologic oncology clinicians in MI, where the typical reported total is $894.
Across 2 payments — averaging $58.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopersurgical, Inc.$100
- Myovant Sciences Inc.$16
Across 20 payments — averaging $6516.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alkermes, Inc.$58K
- Genmab U.S., Inc.$40K
- Merck$32K
What the payments were for
- Food & beverage$10086%
- Education$1614%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopersurgical, Inc. | 1 | $100 |
| Myovant Sciences Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$116 in reported general payments places this provider in the 10th percentile of 43 gynecologic oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 19 | $457,770 |
| LynparzaOlaparib | 28 | $302,749 |
| Prochlorperazine Maleate | 54 | $1,139 |
| Prednisolone Acetate | 12 | $1,056 |
| Dexamethasone | 42 | $769 |
| Olanzapine | 38 | $402 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Ypsilanti
- Angela KueckYpsilanti$761
- Brandy MichaelsYpsilanti$234
- Robert MorrisDetroit$807K
- Ira WinerDetroit$25K
- Morgan TaylorDetroit$23K
- Radhika GogoiDetroit$12K
- Douglas PugmireRochester Hills$9K
- Zaid Al-WahabGrosse Pointe$9K
- Gregory SuttonSaginaw$8K
- Ahmad AwadaDetroit$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.